In hepatocellular carcinoma patients receiving sorafenib, Llovet et al. noticed that baseline VEGF had prognostic value for overall survival, and trend toward enhanced survival benefit was observed in case of high concentration of SCF at baseline. Here, KITLG is linked to hepatocellular carcinoma.